Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures

H He, L Liu, EE Morin, M Liu… - Accounts of chemical …, 2019 - ACS Publications
Conspectus In 1995, the year the first cancer nanomedicine, Doxil, was approved by the
Food and Drug Administration (FDA), only 23 manuscripts appeared in a PubMed search for …
被引用次数：398 相关文章

Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures

H He, L Liu, EE Morin, M Liu… - Accounts of chemical …, 2019 - pubmed.ncbi.nlm.nih.gov
In 1995, the year the first cancer nanomedicine, Doxil, was approved by the Food and Drug
Administration (FDA), only 23 manuscripts appeared in a PubMed search for" nanoparticles …

[引用][C] Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes and Failures

H He, L Liu, EE Morin, M Liu… - Accounts of Chemical …, 2019 - cir.nii.ac.jp
Survey of Clinical Translation of Cancer Nanomedicines—Lessons Learned from Successes
and Failures | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
[PDF] researchgate.net

[PDF][PDF] Survey of Clinical Translation of Cancer Nanomedicines Lessons Learned from Successes and Failures

H He, L Liu, EE Morin, M Liu, A Schwendeman - researchgate.net
CONSPECTUS: In 1995, the year the first cancer nanomedicine, Doxil, was approved by the
Food and Drug Administration (FDA), only 23 manuscripts appeared in a PubMed search for …

Survey of Clinical Translation of Cancer Nanomedicines-Lessons Learned from Successes and Failures.

H He, L Liu, EE Morin, M Liu… - Accounts of Chemical …, 2019 - europepmc.org
In 1995, the year the first cancer nanomedicine, Doxil, was approved by the Food and Drug
Administration (FDA), only 23 manuscripts appeared in a PubMed search for" nanoparticles …